Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase

A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase

(2014) Gregory M. Pastores et al.   BLOOD CELLS MOLECULES AND DISEASES

Taliglucerase alfa: An enzyme replacement therapy using plant cell expression technology

(2014) Gregory A. Grabowski et al.   MOLECULAR GENETICS AND METABOLISM

First plant-made biologic approved

(2012) Jeffrey L Fox   NATURE BIOTECHNOLOGY

Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease

(2011) A. Zimran et al.   BLOOD

Improving the accuracy of MRI spleen and liver volume measurements: A phase III Gaucher disease clinical trial setting as a model

(2010) Luc Bracoud et al.   BLOOD CELLS MOLECULES AND DISEASES

Force Majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease

(2009) Carla E.M. Hollak et al.   BLOOD CELLS MOLECULES AND DISEASES